Multicentric study of cervical cancer screening with human papillomavirus testing and assessment of triage methods in Latin America: the ESTAMPA screening study protocol

Maribel Almonte, Raúl Murillo, Gloria Inés Sánchez, Paula González, Annabelle Ferrera, María Alejandra Picconi, Carolina Wiesner, Aurelio Cruz-Valdez, Eduardo Lazcano-Ponce, Jose Jerónimo, Catterina Ferreccio, Elena Kasamatsu, Laura Mendoza, Guillermo Rodríguez, Alejandro Calderón, Gino Venegas, Verónica Villagra, Silvio Tatti, Laura Fleider, Carolina Terán, Armando Baena, María de la Luz Hernández, Mary Luz Rol, Eric Lucas, Sylvaine Barbier, Arianis Tatiana Ramírez, Silvina Arrossi, María Isabel Rodríguez, Emmanuel González, Marcela Celis, Sandra Martínez, Yuly Salgado, Marina Ortega, Andrea Verónica Beracochea, Natalia Pérez, Margarita Rodríguez de la Peña, María Ramón, Pilar Hernández-Nevarez, Margarita Arboleda-Naranjo, Yessy Cabrera, Brenda Salgado, Laura García, Marco Antonio Retana, María Celeste Colucci, Javier Arias-Stella, Yenny Bellido-Fuentes, María Liz Bobadilla, Gladys Olmedo, Ivone Brito-García, Armando Méndez-Herrera, Lucía Cardinal, Betsy Flores, Jhacquelin Peñaranda, Josefina Martínez-Better, Ana Soilán, Jacqueline Figueroa, Benedicta Caserta, Carlos Sosa, Adrián Moreno, Juan Mural, Franco Doimi, Diana Giménez, Hernando Rodríguez, Oscar Lora, Silvana Luciani, Nathalie Broutet, Teresa Darragh, Rolando Herrero, Maribel Almonte, Raúl Murillo, Gloria Inés Sánchez, Paula González, Annabelle Ferrera, María Alejandra Picconi, Carolina Wiesner, Aurelio Cruz-Valdez, Eduardo Lazcano-Ponce, Jose Jerónimo, Catterina Ferreccio, Elena Kasamatsu, Laura Mendoza, Guillermo Rodríguez, Alejandro Calderón, Gino Venegas, Verónica Villagra, Silvio Tatti, Laura Fleider, Carolina Terán, Armando Baena, María de la Luz Hernández, Mary Luz Rol, Eric Lucas, Sylvaine Barbier, Arianis Tatiana Ramírez, Silvina Arrossi, María Isabel Rodríguez, Emmanuel González, Marcela Celis, Sandra Martínez, Yuly Salgado, Marina Ortega, Andrea Verónica Beracochea, Natalia Pérez, Margarita Rodríguez de la Peña, María Ramón, Pilar Hernández-Nevarez, Margarita Arboleda-Naranjo, Yessy Cabrera, Brenda Salgado, Laura García, Marco Antonio Retana, María Celeste Colucci, Javier Arias-Stella, Yenny Bellido-Fuentes, María Liz Bobadilla, Gladys Olmedo, Ivone Brito-García, Armando Méndez-Herrera, Lucía Cardinal, Betsy Flores, Jhacquelin Peñaranda, Josefina Martínez-Better, Ana Soilán, Jacqueline Figueroa, Benedicta Caserta, Carlos Sosa, Adrián Moreno, Juan Mural, Franco Doimi, Diana Giménez, Hernando Rodríguez, Oscar Lora, Silvana Luciani, Nathalie Broutet, Teresa Darragh, Rolando Herrero

Abstract

Introduction: Human papillomavirus (HPV) testing is replacing cytology in primary screening. Its limited specificity demands using a second (triage) test to better identify women at high-risk of cervical disease. Cytology represents the immediate triage but its low sensitivity might hamper HPV testing sensitivity, particularly in low-income and middle-income countries (LMICs), where cytology performance has been suboptimal. The ESTAMPA (EStudio multicéntrico de TAMizaje y triaje de cáncer de cuello uterino con pruebas del virus del PApiloma humano; Spanish acronym) study will: (1) evaluate the performance of different triage techniques to detect cervical precancer and (2) inform on how to implement HPV-based screening programmes in LMIC.

Methods and analysis: Women aged 30-64 years are screened with HPV testing and Pap across 12 study centres in Latin America. Screened positives have colposcopy with biopsy and treatment of lesions. Women with no evident disease are recalled 18 months later for another HPV test; those HPV-positive undergo colposcopy with biopsy and treatment as needed. Biological specimens are collected in different visits for triage testing, which is not used for clinical management. The study outcome is histological high-grade squamous intraepithelial or worse lesions (HSIL+) under the lower anogenital squamous terminology. About 50 000 women will be screened and 500 HSIL+ cases detected (at initial and 18 months screening). Performance measures (sensitivity, specificity and predictive values) of triage techniques to detect HSIL+ will be estimated and compared with adjustment by age and study centre.

Ethics and dissemination: The study protocol has been approved by the Ethics Committee of the International Agency for Research on Cancer (IARC), of the Pan American Health Organisation (PAHO) and by those in each participating centre. A Data and Safety Monitoring Board (DSMB) has been established to monitor progress of the study, assure participant safety, advice on scientific conduct and analysis and suggest protocol improvements. Study findings will be published in peer-reviewed journals and presented at scientific meetings.

Trial registration number: NCT01881659.

Keywords: colposcopy; gynaecological oncology; molecular diagnostics; preventive medicine; public health; risk management.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

Figures

Figure 1
Figure 1
Flowchart of study protocol. HPV, human papillomavirus; LLETZ, large loop excision of the transformation zone; VIA, visual inspection with acetic acid.
Figure 2
Figure 2
Clinical management of women in the study cohort. CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; LLETZ, large loop excision of the transformation zone; MDT, multidisciplinary team.
Figure 3
Figure 3
Sample management and use. CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; LBC, liquid-based cytology; PC, PreservCyt; QC, quality control.
Figure 4
Figure 4
Study endpoint adjudication process. CIN, cervical intraepithelial neoplasia; HSIL, high-grade squamous intraepithelial lesion.
Figure 5
Figure 5
ESTAMPA study network. EQA, External Quality Assessment; GCPs, Good Clinical Practices; IARC, International Agency for Research on Cancer.

References

    1. Ferlay J, Ervik M, Lam F, et al. . Global cancer Observatory: cancer today Lyon, France: international agency for research on cancer, 2018. Available: [Accessed 01 Jul 2019].
    1. Arbyn M, Weiderpass E, Bruni L, et al. . Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 2020;8:e191–203. 10.1016/S2214-109X(19)30482-6
    1. Rodríguez AC, Schiffman M, Herrero R, et al. . Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010;102:315–24. 10.1093/jnci/djq001
    1. Arbyn M, Xu L, Simoens C, et al. . Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev 2018;5:CD009069. 10.1002/14651858.CD009069.pub3
    1. Arbyn M, Smith SB, Temin S, et al. . Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ 2018;363:k4823. 10.1136/bmj.k4823
    1. Darragh TM, Colgan TJ, Cox JT, et al. . The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American pathologists and the American Society for colposcopy and cervical pathology. Arch Pathol Lab Med 2012;136:1266–97. 10.5858/arpa.LGT200570
    1. Almonte M, Ferreccio C, Winkler JL, et al. . Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. Int J Cancer 2007;121:796–802. 10.1002/ijc.22757
    1. Arbyn M, Sankaranarayanan R, Muwonge R, et al. . Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer 2008;123:153–60. 10.1002/ijc.23489
    1. Ngoma T, Muwonge R, Mwaiselage J, et al. . Evaluation of cervical visual inspection screening in Dar ES Salaam, Tanzania. Int J Gynaecol Obstet 2010;109:100–4. 10.1016/j.ijgo.2009.11.025
    1. Almonte M, Ferreccio C, Luciani S, et al. . Visual inspection after acetic acid (via) is highly heterogeneous in primary cervical screening in Amazonian Peru. PLoS One 2015;10:e0115355. 10.1371/journal.pone.0115355
    1. Sankaranarayanan R, Esmy PO, Rajkumar R, et al. . Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007;370:398–406. 10.1016/S0140-6736(07)61195-7
    1. Dasgupta S, Bhattacharya S. Is visual inspection with acetic acid better than cervical cytology to screen women ≥ 40 years of age for carcinoma cervix? A cross-sectional study on proportion of screen-positive women (by via and cervical cytology) having CIN II/III lesion on cervical biopsy: difference between two age groups and among screening methods. Arch Gynecol Obstet 2012;285:1731–6. 10.1007/s00404-012-2228-3
    1. Muwonge R, Wesley RS, Nene BM, et al. . Evaluation of cytology and visual triage of human papillomavirus-positive women in cervical cancer prevention in India. Int J Cancer 2014;134:2902–9. 10.1002/ijc.28627
    1. Santesso N, Mustafa RA, Schünemann HJ, et al. . World Health organization guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer. Int J Gynaecol Obstet 2016;132:252–8. 10.1016/j.ijgo.2015.07.038
    1. Castle PE, Bulten J, Confortini M, et al. . Age-Specific patterns of unsatisfactory results for conventional Pap smears and liquid-based cytology: data from two randomised clinical trials. BJOG 2010;117:1067–73. 10.1111/j.1471-0528.2010.02650.x
    1. Arbyn M, Bergeron C, Klinkhamer P, et al. . Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 2008;111:167–77. 10.1097/01.AOG.0000296488.85807.b3
    1. Siebers AG, Klinkhamer PJJM, Grefte JMM, et al. . Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA 2009;302:1757–64. 10.1001/jama.2009.1569
    1. Yu K, Hyun N, Fetterman B, et al. . Automated cervical screening and triage, based on HPV testing and Computer-Interpreted cytology. J Natl Cancer Inst 2018;110:1222–8. 10.1093/jnci/djy044
    1. Moriarty AT, Nayar R, Arnold T, et al. . The Tahoe study: bias in the interpretation of Papanicolaou test results when human papillomavirus status is known. Arch Pathol Lab Med 2014;138:1182–5. 10.5858/arpa.2012-0115-CP
    1. Benoy IH, Vanden Broeck D, Ruymbeke MJ, et al. . Prior knowledge of HPV status improves detection of CIN2+ by cytology screening. Am J Obstet Gynecol 2011;205:569.e1–7. 10.1016/j.ajog.2011.06.101
    1. Bergeron C, Giorgi-Rossi P, Cas F, et al. . Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial. J Natl Cancer Inst 2015;107. 10.1093/jnci/dju423
    1. Richardson LA, El-Zein M, Ramanakumar AV, et al. . Hpv DNA testing with cytology triage in cervical cancer screening: influence of revealing HPV infection status. Cancer Cytopathol 2015;123:745–54. 10.1002/cncy.21596
    1. Saslow D, Solomon D, Lawson HW, et al. . American cancer Society, American Society for colposcopy and cervical pathology, and American Society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012;62:147–72. 10.3322/caac.21139
    1. Rijkaart DC, Berkhof J, van Kemenade FJ, et al. . Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012;130:602–10. 10.1002/ijc.26056
    1. Gago J, Paolino M, Arrossi S. Factors associated with low adherence to cervical cancer follow-up retest among HPV+/ cytology negative women: a study in programmatic context in a low-income population in Argentina. BMC Cancer 2019;19:367. 10.1186/s12885-019-5583-7
    1. Schiffman M, Glass AG, Wentzensen N, et al. . A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser cohort study. Cancer Epidemiol Biomarkers Prev 2011;20:1398–409. 10.1158/1055-9965.EPI-11-0206
    1. Adcock R, Cuzick J, Hunt WC, et al. . Role of HPV genotype, multiple infections, and viral load on the risk of high-grade cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2019;28:1816–24. 10.1158/1055-9965.EPI-19-0239
    1. Xi LF, Schiffman M, Hughes JP, et al. . Changes in DNA level of oncogenic human papillomaviruses other than types 16 and 18 in relation to risk of cervical intraepithelial neoplasia grades 2 and 3. Cancer Epidemiol Biomarkers Prev 2019;28:1388–94. 10.1158/1055-9965.EPI-18-0802
    1. Ibeanu OA. Molecular pathogenesis of cervical cancer. Cancer Biol Ther 2011;11:295–306. 10.4161/cbt.11.3.14686
    1. Schweizer J, Lu PS, Mahoney CW, et al. . Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer. J Clin Microbiol 2010;48:4646–8. 10.1128/JCM.01315-10
    1. Ferrera A, Valladares W, Cabrera Y, et al. . Performance of an HPV 16/18 E6 oncoprotein test for detection of cervical precancer and cancer. Int J Cancer 2019;145:2042–50. 10.1002/ijc.32156
    1. Torres KL, Mariño JM, Pires Rocha DA, et al. . Self-Sampling coupled to the detection of HPV 16 and 18 E6 protein: a promising option for detection of cervical malignancies in remote areas. PLoS One 2018;13:e0201262. 10.1371/journal.pone.0201262
    1. Yu L, Jiang M, Qu P, et al. . Clinical evaluation of human papillomavirus 16/18 oncoprotein test for cervical cancer screening and HPV positive women triage. Int J Cancer 2018;143:813–22. 10.1002/ijc.31368
    1. Tsoumpou I, Arbyn M, Kyrgiou M, et al. . p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 2009;35:210–20. 10.1016/j.ctrv.2008.10.005
    1. Carozzi F, Confortini M, Dalla Palma P, et al. . Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2008;9:937–45. 10.1016/S1470-2045(08)70208-0
    1. Sahasrabuddhe VV, Luhn P, Wentzensen N. Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts. Future Microbiol 2011;6:1083–98. 10.2217/fmb.11.87
    1. Wentzensen N, Clarke MA, Bremer R, et al. . Clinical evaluation of human papillomavirus screening with p16/Ki-67 dual stain triage in a large organized cervical cancer screening program. JAMA Intern Med 2019;179:881–8. 10.1001/jamainternmed.2019.0306
    1. Chang C-C, Huang R-L, Liao Y-P, et al. . Concordance analysis of methylation biomarkers detection in self-collected and physician-collected samples in cervical neoplasm. BMC Cancer 2015;15:418. 10.1186/s12885-015-1411-x
    1. Wentzensen N, Sherman ME, Schiffman M, et al. . Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol 2009;112:293–9. 10.1016/j.ygyno.2008.10.012
    1. Clarke MA, Luhn P, Gage JC, et al. . Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer. Int J Cancer 2017;141:701–10. 10.1002/ijc.30781
    1. Mirabello L, Sun C, Ghosh A, et al. . Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J Natl Cancer Inst 2012;104:556–65. 10.1093/jnci/djs135
    1. Wentzensen N, Sun C, Ghosh A, et al. . Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst 2012;104:1738–49. 10.1093/jnci/djs425
    1. Connor RJ. Sample size for testing differences in proportions for the paired-sample design. Biometrics 1987;43:207–11. 10.2307/2531961
    1. Ting J, Rositch AF, Taylor SM, et al. . Worldwide incidence of cervical lesions: a systematic review. Epidemiol Infect 2015;143:225–41. 10.1017/S0950268814001356
    1. Demarco M, Lorey TS, Fetterman B, et al. . Risks of CIN 2+, CIN 3+, and cancer by cytology and human papillomavirus status: the foundation of Risk-Based cervical screening guidelines. J Low Genit Tract Dis 2017;21:261–7. 10.1097/LGT.0000000000000343

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit